ReviewCurrent pharmaceutical design2010
Pharmacogenetics of alcohol and alcohol dependence treatment.
Review in Current pharmaceutical design, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it, 62 citations in OpenAlex.
- Genetic contributions to alcohol use disorder treatment outcomes: a genome-wide pharmacogenomics study.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2021Pooled it
- Real-time assessment of alcohol craving and naltrexone treatment responsiveness in a randomized clinical trial.Addictive behaviors · 2018Trial
- GRIK1 and GABRA2 Variants Have Distinct Effects on the Dose-Related Subjective Response to Intravenous Alcohol in Healthy Social Drinkers.Alcoholism, clinical and experimental research · 2017Trial
- Social network moderators of naltrexone and behavioral treatment effects on heavy drinking in the COMBINE study.Alcoholism, clinical and experimental research · 2015Trial
- Variation in OPRM1 moderates the effect of desire to drink on subsequent drinking and its attenuation by naltrexone treatment.Addiction biology · 2013Trial
- Heroin addiction modulates transcription factor binding in regulatory regions of the human putamen.Scientific reports · 2026Article
- Disentangling between- and within-person alcohol and expectancy effects on acute alcohol craving.Psychopharmacology · 2023Article
- Effects of CYP2C19*17 Genetic Polymorphisms on the Steady-State Concentration of Diazepam in Patients With Alcohol Withdrawal Syndrome.Hospital pharmacy · 2021Article
- TSPAN5 influences serotonin and kynurenine: pharmacogenomic mechanisms related to alcohol use disorder and acamprosate treatment response.Molecular psychiatry · 2021Article
- The Effects of Statins on Neurotransmission and Their Neuroprotective Role in Neurological and Psychiatric Disorders.Molecules (Basel, Switzerland) · 2021Review
- The future of translational research on alcohol use disorder.Addiction biology · 2021Article
- Dopamine in Health and Disease: Much More Than a Neurotransmitter.Biomedicines · 2021Review
- The Benefits of Olanzapine in Palliating Symptoms.Current treatment options in oncology · 2020Review
- OPRM1 Moderates Daily Associations of Naltrexone Adherence With Alcohol Consumption: Preliminary Evidence From a Mobile Health Trial.Alcoholism, clinical and experimental research · 2020Article
- On the path towards personalized medicine: Implications of pharmacogenetic studies of alcohol use disorder medications.Expert review of precision medicine and drug development · 2020Article
- Pharmacogenetics of alcohol addiction: current perspectives.The application of clinical genetics · 2019Article
- A Whole Methylome Study of Ethanol Exposure in Brain and Blood: An Exploration of the Utility of Peripheral Blood as Proxy Tissue for Brain in Alcohol Methylation Studies.Alcoholism, clinical and experimental research · 2018Article
- Article
- Genetic studies of alcohol dependence in the context of the addiction cycle.Neuropharmacology · 2017Review
- ADHD and Present Hedonism: time perspective as a potential diagnostic and therapeutic tool.Neuropsychiatric disease and treatment · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
In this article, we review studies of genetic moderators of the response to medications to treat alcohol dependence, the acute response to alcohol, and the response to the psychotherapeutic treatment of heavy drinking. We consider four neurotransmitter systems: opioidergic, dopaminergic, GABAergic, and glutamatergic and focus on one receptor protein in each: OPRM1 (the &#micro;-opioid receptor gene), DRD4 (the D(4) dopamine receptor gene), GABRA2 (GABA(A) receptor alpha-2 subunit gene), and GRIK1 (the kainite receptor GluR5 subunit gene). We conclude that because parallel developments in alcoholism treatment and the genetics of alcohol dependence are beginning to converge, using genotypic information, it may be possible to match patients with specific treatments. Of greatest clinical relevance is the finding that the presence of an Asp40 allele in OPRM1 modestly predicts a better response to naltrexone treatment. Promising findings include the observations that a polymorphism in GABRA2 predicts the response to specific psychotherapies; a polymorphism in DRD4 predicts the effects of the antipsychotic olanzapine on craving for alcohol and drinking behavior; and a polymorphism in GRIKI predicts adverse events resulting from treatment with the anticonvulsant topiramate. Although variants in other genes have been associated with the risk for alcohol dependence, they have not been studied as moderators of the response either to treatment or acute alcohol administration. We recommend that, whenever possible, treatment trials include the collection of DNA samples to permit pharmacogenetic analyses, and that such analyses look broadly for relevant genetic variation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.